Thymosin beta-4
InvestigationalActin-binding regenerative peptide
Also known as: Tβ4, RGN-259, thymosin beta 4
A real evidence base, with gaps
- Regulatory standing. In clinical trials, not yet approved
- Limited human data. Some human data exists, not conclusive
- Registered human trials. 18 registered studies on ClinicalTrials.gov, most advanced Phase 3
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Thymosin beta-4 is a naturally occurring 43-amino-acid peptide found in most human cells, where it binds actin and helps regulate cell structure and movement. It is thought to influence tissue repair by affecting cell migration, blood vessel formation, and inflammation. RGN-259 is an investigational eye-drop formulation, and TB-500 is a related synthetic fragment sold outside medical channels, which is not the same as the studied product.
What the evidence shows
Thymosin beta-4 is not FDA-approved for any use. There are 18 registered human trials, reaching Phase 3 mainly for eye conditions such as dry eye and neurotrophic keratitis, with mixed results, while most of the 684 published papers are laboratory or animal studies, so benefits in humans remain unproven.
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers
A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Molecular mechanisms controlling actin filament dynamics in nonmuscle cells.
How profilin promotes actin filament assembly in the presence of thymosin beta 4.
Early and progressive accumulation of reactive microglia in the Huntington disease brain.
Effects of jasplakinolide on the kinetics of actin polymerization. An explanation for certain in vivo observations.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.